Background Impulsivity is poorly planned, premature or inappropriate behaviour, and deficits in impulse control are linked to a number of neuropsychiatric disorders. There are a number of theories relating to the neural basis of impulsivity, but the precise molecular mechanisms of impulse control are not clearly understood. Motor impulsivity has been observed in adult zebrafish, but in order to increase throughput it would be beneficial if early markers could be identified in larvae. One such method was recently shown to have some potential efficacy in zebrafish larvae, relating to an ADHD morphant (lphn3.1) showing increases in motor 'peaks' during free swimming behaviour.
Abstract
Background Impulsivity is poorly planned, premature or inappropriate behaviour, and deficits in impulse control are linked to a number of neuropsychiatric disorders. There are a number of theories relating to the neural basis of impulsivity, but the precise molecular mechanisms of impulse control are not clearly understood. Motor impulsivity has been observed in adult zebrafish, but in order to increase throughput it would be beneficial if early markers could be identified in larvae. One such method was recently shown to have some potential efficacy in zebrafish larvae, relating to an ADHD morphant (lphn3.1) showing increases in motor 'peaks' during free swimming behaviour.
Objective
The aim of this study was to carry out a pharmacological evaluation of motor 'peaks' as a measure of motor impulsivity in larval zebrafish, as well as evaluate the behaviour of mutant lines that might be predicted to show variation in motor impulsivity.
Method 6dpf zebrafish larvae were filmed for 90-seconds following incubation in amisulpride (a DRD2/3 antagonist), nicotine, apomorphine (a non-specific dopamine agonist), atomoxetine (a norepinephrine reuptake inhibitor), and methylphenidate (a combined dopamine/norepinephrine agonist). We also filmed 6dpf larvae homozygous and heterozygous for mutations in pink1, disc1, and ache. In all larvae, we analysed distance moved and motor 'peaks', calculated as number of 3-second bins in which the larva traveled > 10mm.
Impulsivity is characterized as behavior that is poorly planned, premature or inappropriate to the context in which it is performed (1) . Impulsivity can be operationally defined as reduced 'self-control' (e.g., choosing a relatively higher value reward after a delay over a relatively lower, more immediate reward (2)), or as a reduced ability to inhibit a pre-potent response (e.g., as measured by ability to withhold responding during a pre-stimulus interval on a continuous performance task (3) ). The inability to withhold a pre-potent response, or 'motor' impulsivity (4) , is an important behavioral predictor of a number of neuropsychiatric disorders, such as attention deficit-hyperactivity disorder (ADHD; (5)), personality disorders (6) , mania (7) , substance abuse disorders (8) and eating disorders (9) . Thus, understanding the molecular and cellular basis of impulsivity is a priority in biological psychiatry in order to improve treatments (10) .
Recently, zebrafish have proved useful as an animal model of impulsivity. For example, Parker and colleagues have found evidence for motor impulsivity in a zebrafish version of the 5-choice serial reaction time task (5CSRT (11, 12) ), the 'gold-standard' test for motor impulsivity in rodents (13) . During the 5CSRT, the animal is required to continuously monitor which one of five stimuli are presented following a delay (a pre-stimulus interval; PSI) in order to receive a food reinforcer. Impulsivity can be operationally defined in the context of this task by the inability to withhold responding during the PSI. We demonstrated that motor impulsivity may be controlled by noradrenergic circuits in zebrafish (14) , as is the case in rodents (15) and humans (16) , with all of these species showing a dose-dependent reduction in impulsivity following administration of the noradrenergic reuptake inhibitor, atomoxetine. The effects we observed were in adult (3 months post-fertilization) zebrafish. Adult zebrafish represent a refined model system for the study of the molecular basis of disease over rodents, in particular owing to their small size and high reproductive rate, but also their genetic tractability and resilience to mutation (17) . Indeed, we recently demonstrated that zebrafish heterozygous for a null mutation in the acetylcholinesterase gene showed lower levels of impulsivity in our 5CSRT test (18) .
An alternative method of quantifying impulsivity in zebrafish larvae was proposed by Lange and colleagues, in a study of the behavioral and morphological effects of mutation in a gene that has been linked strongly to ADHD, latrophilin 3 (LPHN3) (19) . Their method involved filming 6-day-post-fertilization (6dpf) larvae for 90 seconds and observing their movement patterns. Interestingly, as well as generally being more hyperactive, the lphn3 morphant showed idiosyncratic motor 'peaks', which the authors suggested may represent motor impulsivity. It may be, therefore, that larvae could show early signs or behavioral markers of impulsivity. Zebrafish larvae are of significant benefit as a model system for the drug exposure on account of their potential for setting up high-throughput screens. Thus if we are able to identify early larval markers of impulsivity, this would increase the efficacy of testing novel pharmacotherapeutics for impulsivity-related neuropsychiatric disorders.
The aim of the current study was to examine the utility of larval measures of impulsivity. The objectives were first to carry out a pharmacological validation using drugs that would be hypothesized to increase impulsivity (DRD2/D3 receptor antagonist amisulpride, the nonspecific DA agonist apomorphine, and the nAChR agonist nicotine), followed by impulsivityreducing drugs (methylphenidate and atomoxetine). The second phase of the study was to examine the performance on this task of genetic lines that have previously been shown to have variability in impulsivity in zebrafish, ache (18) . We also hypothesized that there might be differences in mutant lines where the mutated genes had previously been linked to impulsivity in other species. These lines included ache (18) , but also disc1 (20) , a putative model of schizophrenia, and pink-1 (21), a putative model of Parkinson's disease. Both PINK1 (22) and DISC1 (23) have been linked to increased impulsivity in previous studies.
Materials and methods

Subjects
Zebrafish larvae were bred in the aquarium facility at Queen Mary University of London according to published protocols (24) . Larvae were grown in Petri dishes to 6dpf in an incubator (28 o C) prior to testing. Care was taken to ensure that larvae used for testing were of a similar size and developmental period as this would have a major impact upon performance on the locomotor tasks. Prior to testing, larvae were pipetted carefully out of their petri dishes and placed in the testing plates in 2ml of aquarium water. The following mutant lines were acquired from ZIRC (www.zebrafish.org). ache sb55/+ were acquired as heterozygote outcrosses. Because ache -/-are not viable, we were only able to examine the larvae from ache +/-incrossed adults. This would result in 67% ache +/-in the sample (and 33% ache +/+ ; ache -/-is homozygous lethal by day 6). pink1 -/-were bred by in-crossing homozygote siblings, and heterozygotes were bred by crossing pink1 -/-with wild-type (TU) siblings. disc1 fh292/fh292 were acquired as heterozygote outcrosses. disc1 -/-were bred by incrossing homozygote siblings, and heterozygotes were bred by crossing disc1 -/-with wildtype (TU) siblings.
Materials
Larvae were filmed in a custom-made larval filming tower (Fig 1; TrackSys, Nottingham, UK), which integrated with Ethovision XT software (Noldus Information Technology, Wageningen, Netherlands). During filming, larvae were placed in clear 12-well-plates, with one larva/well. Each well contained 2ml aquarium water (24 o C).
Drugs
Drugs were dissolved in aquarium water as a stock solution (except amisulpride; see below), and added to the individual wells of the plate prior to filming the fish. Drugs used were amisulpride (Tocris Bioscience, UK), nicotine hydrogen tartrate (Sigma, UK), apomorphine (Sigma, UK), methylphenidate hydrochloride (Sigma, UK), and atomoxetine hydrochloride (Sigma, UK). All drugs were first made into stock solutions (in aquarium H 2 O) stocks through serial dilution to reach concentrations that allowed for 100µl of stock to be added to 2ml H 2 O to reach the required well concentration. This ensured that the same volume of solution was added to each well containing a larva. Amisulpride was a solid, and 8mg was initially dissolved in 1ml 100% DMSO. This was then added to 200ml H20. These stock solutions were added to aquarium-treated water to create a diluted stock solution to add to the wells in 100µl aliquots. For the amisulpride-treated larvae, all solutions were made up to give a final concentration of 0.0025% DMSO -that required for the highest amisulpride dose. 
Behavioral recording and peak analysis
Larvae were first habituated for 90-seconds, and then filmed for 90-seconds, in accordance with previous work (19) . For drug trials, the initial 90-seconds constituted the incubation period in the drug. This incubation time was based on previous work with zebrafish larvae and locomotor responses to nicotine; Pezhold and colleagues found that zebrafish larvae respond to nicotine after 30-seconds incubation in the drug (25), thus 90-seconds appeared to be sufficient to allow uptake of the drug. However, for amisulpride, because there was no measureable difference after 90-sec incubation, we also incubated for 30-min to ensure sufficient time for uptake. Movement data, including distance travelled (mm) were collected in Ethovision XT. Peaks were defined as movements of >10mm in 3-seconds of filming. Specifically, all distance data was outputted by Ethovision in 3-second time bins. Once all the data were collected, we created a list of every 3-second bin and calculated the mean distance, as well as the maximum distance (Max) for each larva. We then subtracted the mean overall distance for each 3 min from the mean value of Max, giving a total value of 10.8mm. We therefore set the value for a burst of movement as >10mm in 3 seconds. The total number of peaks for each larva was then ascertained, as was the total distance moved over the 90-seconds of filming.
Data analysis
All distance data were analyzed using a fixed-effects univariate analysis of variance (ANOVA), with the dependent variable distance (mm) and the independent variable either dose (for the drugs used) or genotype. The only exception was ache sb55/+ which was analyzed using a t-test. After fitting all models, residuals were checked for Gaussian error structure. Motor impulsivity was measured using an analysis of the number of 'peaks' for each fish. The errors were Poisson distributed (count data) and thus the peaks were analyzed using a Generalized Linear Model with a Poisson distribution (log link). Again, the independent variable was either dose (for drugs) or genotype.
Results
Can motor impulsivity be induced pharmacologically?
.00 .06 . 13 . To examine if motor impulsivity could be induced pharmacologically, we chose three drugs, amisulpride, nicotine and apomorphine. Amisulpride is a selective dopamine receptor (DR) D2/D3 sub-type antagonist. As reduction in DRD2 is associated with increased impulsivity in rodents (26), we reasoned that if our procedure was probing motor impulsivity, pharmacological blockade of D2/D3 receptors would increase peaks in a dose-dependent manner. Figure 2a displays the distance traveled as a function of dose of amisulpride. There was no significant effect of amisulpride on distance traveled, F < 1. Figure 2b displays the numbers of peaks as a function of dose of amisulpride. A generalized linear model showed no overall effect of dose on peaks,  2 = 8.8, df = 4, P = 0.07. Collectively, these data suggest that amisulpride does not affect larvae at the doses tested here. It is possible that the reason that we did not observe an effect on locomotor behaviour was the result of insufficient incubation time. Indeed, a previous study with adult zebrafish incubated the animals for 30-min (27) . Thus we incubated the larvae in 0, 0.13 and 0.5mg/l amisulpride for 30-min prior to filming as a comparison. The results were very similar to 90-sec incubation. There was no effect of dose of amisulpride on distance traveled in the 90-sec filming (0mg/l = 589.39±39.4mm; 0.13mg/l = 642.29±38.9mm; 0.5mg/l = 666.24±38.9), F (2,140) = 1.01, P = 0.37. In addition, there was no effect of dose of amisulpride on number of peaks during the 90-sec filming (0mg/l = 6.06±0.36; 0.13mg/l = 6.17±0.36; 0.5mg/l = 6.88±0.38),  2 = 2.89, df = 2, P = 0.24.
The second drug tested was nicotine. Acute nicotine is known to increase impulsivity in rats through activation of nAChR 42 (28) . Figure 2c displays the distance traveled as a function of nicotine dose. A univariate fixed-effect ANOVA revealed that there was a main effect of dose on distance traveled, F (4,198) = 7.3, P < 0.001. Post-hoc Tukey HSD tests revealed the differences were between the control (0µM) and 3µM, 6µM and 12µM doses (Ps < 0.001). There was no difference between distance traveled in the 0µM and 1.5µM doses (P = 0.5). Figure 2d displays the number of peaks as a function of dose of nicotine. A generalized linear model revealed no overall effect of dose on peaks,  2 = 6.5, df = 4, P = 0.17. Previous studies had shown that nicotine is behaviourally activating after an incubation time of 30-sec (25), and we observed a dose-dependent effect on locomotor responding of the drug, thus we did not incubate for longer as a comparison for this drug.
Finally, we examined the effects of the non-selective dopamine agonist, apomorphine. Apomorphine is a non-selective dopamine agonist. It is known to activate both D 2 and, to a lesser extent, D 1 receptors. It has also been shown to act as an antagonist of 5-HT2 and α-adrenergic receptors, both with high affinity (29) . Figure 2e displays the distance traveled as a function of apomorphine dose. A univariate fixed-effect ANOVA revealed no main effect of dose on distance traveled (F < 1). Figure 2f displays the number of peaks as a function of dose of apomorphine. A generalized linear model revealed a main effect of dose on peaks,  2 = 168.6, df = 3, P < 0.001, with more peaks at 7µM (P < 0.001) and 37µM (P < 0.001) as compared to 0µM control. There was no difference between control and 18µM, however, suggesting a bimodal dose-activating effect of the drug on locomotor peaks. Fig. 3 . Dose dependent effects of atomoxetine on reducing (a) distance traveled and (b) motor peaks. *P ≤ 0.05
What is the effect of drugs that have therapeutic efficacy in the treatment of impulsivity on motor peaks?
We examined if atomoxetine, a norepinephrine reuptake inhibitor that reduces impulsivity in humans (30) , rodents (31) and recently, adult zebrafish (32), affected distance traveled and peaks in larvae. We chose three doses of atomoxetine (0µM, 1µM and 2µM). Figure 3a displays the dose-dependent effects of atomoxetine on distance traveled (mm). A univariate ANOVA revealed a no significant main effect of atomoxetine on distance traveled, F (2,125) = 1.89, P = 0.16. Figure 3b displays the dose-dependent effect of atomoxetine on the number of peaks. A generalized linear model revealed a main effect of atomoxetine,  2 = 6.24, df = 2, P = 0.044, with 2µM atomoxetine reducing peaks relative to 0µM (P = 0.03) and 1µM (P = 0.03). There was no difference between 0µM and 1µM (P = 0.96). Next we examine the effects of methylphenidate, a combined dopamine/noradrenaline reuptake inhibitor used that reduces impulsivity in humans (33) and rodents (34), on peaks and distance in larval zebrafish. Again, we chose three doses of methylphenidate (0µM, 7.5µM and 15µM). Figure 4a displays the dose-dependent effects of methylphenidate on distance traveled (mm). A univariate ANOVA revealed no significant main effects of methylphenidate on distance traveled (F < 1). Figure 4b displays the dose-dependent effect of methylphenidate on the number of peaks. A generalized linear model revealed a main effect of methylphenidate,  2 = 6.26, df = 2, P = 0.04, with more peaks at 15µM than at 0µM (P = 0.013) and at 7.5µM (P = 0.03). There was no difference in peaks between 0µM and 7.5µM atomoxetine (P = 0.74).
Collectively, these data suggest that although there is a dose-dependent effect on movement by nicotine, there is no effect on motor impulsivity as operationally defined through number of peaks. In addition, both atomoxetine and methylphenidate dosedependently reduced peaks, but not distance traveled.
Can motor impulsivity be measured in mutant lines?
To examine if larval motor peaks could be a potential marker for adult impulsivity, we tested three mutant lines with either hypothesized (disc1, pink1) or previously demonstrated (ache) differences in impulsivity. . A generalized linear model revealed a significant main effect of mutation on peaks,  2 = 8.38, df = 2, P = 0.015, with disc1 -/-larvae having significantly fewer peaks than disc1 +/+ siblings (P < 0.01). Although disc1 +/-larvae appeared to have fewer peaks than disc1
, this was not statistically significant (P = 0.08). 
Discussion
The aim of this study was to examine the utility of motor 'peaks' a putative measure of motor impulsivity for larval zebrafish. The method was based on a previous report of motor impulsivity in a morpholino oligo morphant zebrafish harboring a knockdown of lphn3.1, a model for ADHD (19) . We carried out both a pharmacological examination and an examination of mutant lines that would be expected to show differences in motor impulsivity. The results suggested that there may be some merit in this method for detecting early markers for variability in impulse control. Most importantly, we observed that drugs that reduce impulsivity in rodent models and humans, atomoxetine and methylphenidate, dose-dependently decreased motor peaks, but had no effect on distance traveled. We found that incubation in nicotine (nAChR agonist) or amisulpride (dopamine DRD2/D3 antagonist), despite showing differences in movement (in the case of nicotine), showed no signs of motor impulsivity, as operationalised by increases in motor peaks. However, we found that incubation in apomorphine (a non-selective dopamine agonist) increased peaks in a bimodal fashion, but had no effects on total distance traveled. Finally, we found that although ache +/-incrossed larvae showed lower movement than ache +/+ incrossed siblings, there were no measureable differences in motor peaks. By contrast, disc1 -/-showed reductions in motor peaks as compared to wild-type siblings but no changes in movement, suggesting reduced motor impulsivity. There were no observable differences in pink1 -/-.
In both human (35) and adult laboratory rats (36, 37) and zebrafish (19, 32) , atomoxetine dose-dependently reduces impulsivity. Here, at similar doses to our previous findings in adults zebrafish (32), we observed a reduction in motor peaks at 2µM doses. We did not see any corresponding reductions in total distance travelled. Atomoxetine is a selective noradrenaline reuptake inhibitor (29) used commonly to treat symptoms of ADHD (30) , and impulsivity and hyperactivity in other neuropsychiatric disorders (38, 39) . Atomoxetine increases pre-frontal cortical noradrenaline and dopamine, and this is hypothesised to be the mechanism by which the drug reduces impulsivity: i.e., by increasing executive control over behaviour (29, 40) . In addition, recent evidence has suggested that this may be the effect of atomoxetine decreasing the tonic firing rate of locus coeruleus neurons while simultaneously increasing both the excitatory and inhibitory responses to external stimuli (41) . These data suggest that atomoxetine increases the phasic:tonic ratio of locus coeruleus neurons, thus increasing the 'signal to noise ratio', and potentially enhancing cognition. In zebrafish, noradrenergic neurons in the locus coeruleus have been detected from early in brain ontogeny (42, 43) , and alpha-2 adrenergic (adra2a) receptors expression is present in telencephalic cells (44) where there are high concentrations of dopamine cells in zebrafish (45) . In addition, Lange et al (19) demonstrated that atomoxetine rescued behavioural hyperactivity phenotype in lphn3.1 knock-down morphant zebrafish larvae. Interestingly, the number and spatial arrangement of noradrenergic neurons in the locus coeruleus was similar in the morphant and control-injected larvae. However, the morphant larvae had reductions and disorganisation of posterior tuberculum DA neurons, a population that projects to the subpallium, a circuit hypothesised to be similar to the ascending dopaminergic pathways in mammals (45) . It is possible, therefore, that atomoxetine exerts its effects on zebrafish behaviour in a similar manner to that observed in mammals, but this requires further exploration.
Methylphenidate, a non-selective dopaminergic and noradrenergic reuptake inhibitor (46) , has dose dependent therapeutic efficacy in human patients with ADHD (47) . The effects of methylphenidate on impulsivity in animal models are somewhat confusing, with some studies in rodents showing that methylphenidate decreases impulsivity at 10mg/kg (46), but others in rodents (36) and zebrafish (32) finding that this drug, even at relatively low doses (<5mg/kg), increased premature responses in a 5-choice serial reaction time task, suggesting reduced impulse control. It is possible that task-related variables (e.g., the use of variable vs fixed-time pre-stimulus intervals) may have been the reason for these discrepancies. An explanation for the differences between the effects on impulsivity between methylphenidate and atomoxetine relate to the action of the former on increasing, and the latter on decreasing, striatal dopamine levels (29) . Here, we found that methylphenidate dose-dependently reduced motor peaks in the larvae. Comparative studies have failed to find mesencephalic dopamine neurons in zebrafish (48), thus confusing the picture further. It is possible that factors relating to the ontogeny of the dopamine system may explain differences between larval and adult responses to methylphenidate. This will require further examination to be clear. In particular, future studies may examine the effects on dopamine availability in the telencephalon following administration of methylphenidate in larvae and in adult zebrafish.
We found a strong effect of mutation on motor peaks in disc1 fh292/fh292 (null) mutants, with the mutation appearing to reduce the behaviour. disc1 codes for the Disrupted in Schizophrenia 1 protein, which is responsible for various cell-regulatory processes, including differentiation, proliferation, neuronal outgrowth and adhesion (as well as many more). Variants at this locus have been variously associated with the pathogenesis of schizophrenia (49) and Disc1 -/-null mice show high levels of impulsivity (23) . To our knowledge, ours is the first study that has examined phenotypes in juvenile disc1 mutants of any species as a potential marker for adult phenotypes. The reduction in impulsivity in our sample may be explained by species differences. While we found that zebrafish disc1 mutants are less impulsive than wild-type siblings, this is somewhat at odds with evidence from adults of other species. For example, disc1 zebrafish have abnormal brain development which appears to result from the mutation affecting the noncanonical Wnt singaling pathway, in particular in its role in the regulation of convergence during gastrulation (20) . In mice, however, Disc1 acts through -catenin to increase neuronal proliferation during gestation (50) . In zebrafish, the noncanonical Wnt pathway mediates normal neuronal migration, suggesting that this mutation might alter neural circuit formation. This may be the same in mice, but it is not clear how this affects behavioural responses. Finally, there is currently no evidence that disc1 adults show impulsivity, and this also would be an interesting area for future research.
We found no differences in the pink1 mutant. pink1 codes for the PTEN-induced kinase 1 protein, and mutations at this locus have been linked to the heritable, autosomal-recessive form of Parkinson's disease (51) . There is currently fairly limited evidence relating to the effects of this mutation on early behavioural markers in model species, although there is some evidence that adults with variants show increased impulsivity. For example, Kitada et al. (52) found that numbers of dopaminergic neurons and levels of midbrain (striatal) dopamine and DA receptors are not significantly different in Pink1 −/− mice than in wild-type control siblings. However, in zebrafish with a morpholino oligo-induced knockdown of pink1, although there were no marked differences in the numbers of diencephalic dopamine neurons, their organisation and hodology was severely disrupted (21) . In addition, these morphants showed abnormal locomotor activity, including reductions in swimming behaviour. Here, we found no such differences in the pink1 -/-mutant, nor did we observe any differences in motor peaks in this line. In addition, recent work has uncovered the effects of this mutation on increasing reactive oxygen species (ROS) and decreasing antioxidant enzymes. This may suggest that the behavioural deficits observed later in development (adulthood) might be the result of oxidative stress, as opposed to trait differences throughout ontogeny.
We found no differences in the ache sb55/+ , the heterozygotes of which were observed to have lower impulsivity as adults (18) . This may suggest that reductions in impulsivity observed in adult ache +/-are reflective of neurophysiological or neuroanatomical changes later in brain ontogeny. Conversely, we found that the ache +/-had lower movement in terms of distance travelled, something that was not observed in the adults. It is plausible that the reduced distance travelled is indicative that the ache +/-are simply more cautious or 'vigilant' in their behaviour. While evidence that the ache +/-anticipatory responses were lower, we found no evidence for improved accuracy in this line, however, making this interpretation potentially problematic. Further research on the mechanisms of the decrease in motor impulsivity in ache+/-and the changes in the phenotype during brain ontogeny may elucidate the discrepancy between larval and adult motor behaviour. Finally, a drawback of our present study is that as the ache sb55/sb55 mutation is homozygous lethal, we were only able to carry out observations on ache +/-in-cross larvae and compare this to ache +/+ wildtype siblings. This meant that of our mutant larvae, only 66% would be heterozygous for the mutation. To control for this, we ensured that there were more ache +/-incrossed siblings in the sample than ache +/+ ; however, it is plausible that this inability to differentiate accurately masked any effect of the mutation. Sequencing all the larvae was beyond the scope of this study as it was a first-round validation, but this would be a potential improvement for the future.
We observed a bimodal dose-response on locomotor peaks for the non-selective dopamine agonist apomorphine, with an increase in peaks at 7µM and 37µM. There were no effects of the drug on distance traveled. Apomorphine activates both DRD2 and, to a lesser extent, DRD1. DRD1 are generally postsynaptic, and are excitatory. DRD2 are both pre-and postsynaptic, and can be excitatory or inhibitory. The bimodal response to the apomorphine thus may have been the result of differential affinity of the drug to the DRD1 and DRD2, the location of the receptors (DRD2 autoreceptors, or DRD1 and DRD2 postsynaptic receptors) and the consequence of receptor activation (i.e., inhibitory or excitatory).
We found no effects of the DRD2/D3 antagonist, amisulpride on motor peaks or on distance travelled after both 90-seconds and 30-minutes incubation in the drug. This is somewhat at odds with previous work that showed that, in adult zebrafish at least, incubation in 1mg/L amisulpride for 30-mins increased the amount of freezing and the angular velocity of the fish. The differences may reflect that the dose used in our study was too low to cause a change in locomotor behaviour. In humans, genetic variants at the DRD2 locus are related to behavioural inhibition and impulsivity (53) . However, rats high in trait impulsivity, as measured by the 5-choice serial reaction time task, have a reduction of DRD2/3 in the nucleus accumbens (26) , a finding similar to humans with increased impulsivity (54) . More recently the link between DA receptors and impulsivity has been further specified to be imbalanced between DRD2/3 receptors in the shell and core regions of the nucleus accumbens (55); therefore, is It is possible that systemic administration would not induce impulsivity. However, it is not currently clear if zebrafish have a region that is functionally homologous to the nucleus accumbens in mammals, in particular not the anatomical subregions of the core and shell. It would be useful to examine functional heterogeneity of adult zebrafish DRD2/3 and impulsivity in this species as this would help to understand if the species was a suitable complementary model to mammals for looking at DRD2/3 therapeutic pharmacology for impulsivity.
We found that nicotine dose-dependently increased distance traveled, but not motor peaks. Nicotine increasing motor activity in zebrafish larvae is well established, and we replicated this finding here (25). Although nicotine increases impulsivity in mammals (28), we did not find any effects of nicotine on motor peaks in larval zebrafish. This is in line with our previous findings in adult zebrafish, that did not show increases in anticipatory responses in a 5-choice serial reaction time task (18) . Nicotine-induced impulsivity in rats has been suggested either to be caused by a decrease in accuracy of time estimation or general increases in hyperactivity, both known effects of acute nicotine administration (56) . We find here that although increases in activity are clear, there are no related increases in motor peaks. This might suggest that different mechanisms are responsible for zebrafish and mammalian impulsivity, but further research with nicotine and related agonists and antagonists would be required to elucidate.
In summary, we have potentially found evidence for an early marker of adult trait behavioural differences in zebrafish larvae. This has wide-ranging implications not only for increasing throughput of studies, but also for refinement and reduction of adult fish use in in vivo research. It is important to state that we are not suggesting that this measure could replace adult measures, but it appears that this method of early screening of putative genes that are linked to impulsivity may have some merit. There are several drawbacks that need to be addressed. For example, currently although we can reduce baseline motor peaks pharmacologically with atomoxetine and methylphenidate, drugs that reduce impulsivity, we only saw induction of motor peaks pharmacologically with apomorphine given the current exposure time. It may be that our exposure time was not sufficient to induce locomotor peaks in the amisulpride and nicotine-treated larvae. For example, Irons and colleagues (57) demonstrated that dopaminergic drugs have different pharmacological peak effects dependent on duration of exposure in zebrafish larvae. It may be that if the larvae were incubated for longer, peaks would manifest. There is also evidence that the motor peak phenotype can be reduced (19) , and as we have observed here in the disc1 line. Further work on the pharmacology will be essential if this assay is to be adopted in frontline screening programmes, including in particular pharmacological rescue of phenotypes.
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